fibrillation will provide new information about the impact of thrombin inhibition on ischaemic events in diabetic compared with non-diabetic patients. 7, 8 Ongoing studies of the alternative strategy of targeting the principal platelet thrombin receptor, PAR-1, rather than thrombin itself will also reveal the potential of adding a further platelet inhibitor to aspirin and a P2Y 12 inhibitor in high-risk patients.
fibrillation will provide new information about the impact of thrombin inhibition on ischaemic events in diabetic compared with non-diabetic patients. 7, 8 Ongoing studies of the alternative strategy of targeting the principal platelet thrombin receptor, PAR-1, rather than thrombin itself will also reveal the potential of adding a further platelet inhibitor to aspirin and a P2Y 12 inhibitor in high-risk patients. 9 This strategy has the advantage of more limited effects on haemostasis compared with anticoagulant therapies yet potentially synergistic antithrombotic effects 10, 11 and so the clinical trial results are eagerly awaited to determine whether it is possible to reduce rates of myocardial infarction and death without significantly compromising haemostasis.
It is clear that the mechanisms by which diabetes mellitus drives increased propensity to thrombogenesis will continue to be unravelled in future work and our evolving scientific understanding will underpin new therapeutic strategies that reduce morbidity and mortality due to atherothrombosis in patients with diabetes mellitus.
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In an era of increasing incidence of diabetes mellitus, the need to understand the mechanisms of morbidity and mortality in patients afflicted with the disease, and consequently target more effective therapies, becomes ever more pressing. This fact is highlighted by the limited impact of aspirin on atherothrombotic events in patients with diabetes. 1 In this issue, three articles from experts in this field explore the current evidence for the prothrombotic mechanisms underlying the enhanced ischaemic risk associated with diabetes. [2] [3] [4] It is clear that there are many complexities related to numerous known or potential effects of hyperglycaemia on platelet reactivity and coagulation pathways. Added to this is the attenuation of the effects of standard antiplatelet drugs by diabetes and, furthermore, potential prothrombotic effects of hypoglycaemia, and its associated increased adrenergic activity, complicating treatment with hypoglycaemic agents. In view of all these complexities, different targets and strategies will need to be tested in clinical trials in order to establish the best way forward for reducing thrombotic risk.
Clearly some progress has been made to date. The limited effects of aspirin and attenuation of the effects of clopidogrel, as described here by Angiolillo and colleagues, 2,4 explain why more effective inhibitors of the platelet P2Y 12 receptor than clopidogrel yield important reductions in the risk of myocardial infarction and death in diabetic patients with acute coronary syndromes. 5, 6 Yet despite these advances, the risk of ischaemic events remains unacceptably high even when platelet cyclooxygenase-1 and P2Y 12 receptors appear well inhibited. Consequently much more work is needed. Should we target additional pathways in platelets or use adjunctive antithrombin therapies, or both, in diabetic patients who have suffered an acute coronary syndrome? The present expert reviews give us some insights into how this question may be answered and provide rationales for supporting new clinical trials as well as subanalyses of ongoing phase 3 studies. Thrombin seems to be a promising target in view of its pivotal role in both the key elements of thrombus formation, platelet activation and fibrin formation. Thus, analyses of ongoing studies of novel oral anticoagulants in acute coronary syndromes and atrial
